Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia

Therapy resistance is a major challenge in the treatment of cancer. Here, we performed CRISPR-Cas9 screens across a broad range of therapies used in acute myeloid leukemia to identify genomic determinants of drug response. Our screens uncover a selective dependency on RNA splicing factors whose loss...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cancer cell Ročník 41; číslo 1; s. 164
Hlavní autoři:	Wang, Eric, Pineda, Jose Mario Bello, Kim, Won Jun, Chen, Sisi, Bourcier, Jessie, Stahl, Maximilian, Hogg, Simon J, Bewersdorf, Jan Phillipp, Han, Cuijuan, Singer, Michael E, Cui, Daniel, Erickson, Caroline E, Tittley, Steven M, Penson, Alexander V, Knorr, Katherine, Stanley, Robert F, Rahman, Jahan, Krishnamoorthy, Gnana, Fagin, James A, Creger, Emily, McMillan, Elizabeth, Mak, Chi-Ching, Jarvis, Matthew, Bossard, Carine, Beaupre, Darrin M, Bradley, Robert K, Abdel-Wahab, Omar
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 09.01.2023
Témata:	Apoptosis - genetics Bridged Bicyclo Compounds, Heterocyclic - pharmacology Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Cell Line, Tumor Humans Leukemia, Myeloid, Acute - genetics Myeloid Cell Leukemia Sequence 1 Protein - metabolism Protein-Tyrosine Kinases Proto-Oncogene Proteins c-bcl-2 RNA Splicing - genetics RNA-Binding Proteins - genetics CLK acute myeloid leukemia BCL2 XIAP venetoclax DYRK RBM10 RNA splicing
ISSN:	1878-3686, 1878-3686
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!